Agouron has presented new data on three of its anticancer drugs at the American Association for Cancer Research meeting in La Jolla, California, including updated Phase II results with its thymidylate synthase inhibitor Thymitaq (AG337).
Agouron's vice president for clinical affairs, Neil Clendennin, presented data from Phase II trials of Thymitaq in patients with head/neck, prostate, pancreatic, liver, colon and non-small cell lung cancer. He noted that stabilized disease or tumor reductions of less than 50% were observed in some patients in each disease group, but the best results were obtained in the head/neck and liver cancer groups.
Of 19 evaluable patients with head/neck cancer, two experienced partial responses to Thymitaq (greater than 50% reduction in tumor volume), and two patients had complete (100%) responses. Of 18 patients with hepatocellular carcinoma, two had partial responses, while two others had tumor reductions sufficient to permit surgical removal of previously inoperable tumors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze